267 related articles for article (PubMed ID: 23225002)
1. α-Synuclein aggregation and modulating factors.
Paleologou KE; El-Agnaf OM
Subcell Biochem; 2012; 65():109-64. PubMed ID: 23225002
[TBL] [Abstract][Full Text] [Related]
2. Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies.
Oueslati A; Fournier M; Lashuel HA
Prog Brain Res; 2010; 183():115-45. PubMed ID: 20696318
[TBL] [Abstract][Full Text] [Related]
3. Interaction with synphilin-1 promotes inclusion formation of alpha-synuclein: mechanistic insights and pathological implication.
Xie YY; Zhou CJ; Zhou ZR; Hong J; Che MX; Fu QS; Song AX; Lin DH; Hu HY
FASEB J; 2010 Jan; 24(1):196-205. PubMed ID: 19762560
[TBL] [Abstract][Full Text] [Related]
4. Aggregation of alpha-synuclein in the pathogenesis of Parkinson's disease.
Iwatsubo T
J Neurol; 2003 Oct; 250 Suppl 3():III11-4. PubMed ID: 14579119
[TBL] [Abstract][Full Text] [Related]
5. α-Synuclein: membrane interactions and toxicity in Parkinson's disease.
Auluck PK; Caraveo G; Lindquist S
Annu Rev Cell Dev Biol; 2010; 26():211-33. PubMed ID: 20500090
[TBL] [Abstract][Full Text] [Related]
6. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
Chaari A; Hoarau-Véchot J; Ladjimi M
Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
[TBL] [Abstract][Full Text] [Related]
7. Lewy-like aggregation of α-synuclein reduces protein phosphatase 2A activity in vitro and in vivo.
Wu J; Lou H; Alerte TN; Stachowski EK; Chen J; Singleton AB; Hamilton RL; Perez RG
Neuroscience; 2012 Apr; 207():288-97. PubMed ID: 22326202
[TBL] [Abstract][Full Text] [Related]
8. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells.
Luk KC; Song C; O'Brien P; Stieber A; Branch JR; Brunden KR; Trojanowski JQ; Lee VM
Proc Natl Acad Sci U S A; 2009 Nov; 106(47):20051-6. PubMed ID: 19892735
[TBL] [Abstract][Full Text] [Related]
9. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis.
Mehra S; Sahay S; Maji SK
Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):890-908. PubMed ID: 30853581
[TBL] [Abstract][Full Text] [Related]
10. Role of post-translational modifications on the alpha-synuclein aggregation-related pathogenesis of Parkinson's disease.
Yoo H; Lee J; Kim B; Moon H; Jeong H; Lee K; Song WJ; Hur JK; Oh Y
BMB Rep; 2022 Jul; 55(7):323-335. PubMed ID: 35733294
[TBL] [Abstract][Full Text] [Related]
11. α-Synuclein aggregation and transmission in Parkinson's disease: a link to mitochondria and lysosome.
Wang R; Sun H; Ren H; Wang G
Sci China Life Sci; 2020 Dec; 63(12):1850-1859. PubMed ID: 32681494
[TBL] [Abstract][Full Text] [Related]
12. Gelsolin co-occurs with Lewy bodies in vivo and accelerates α-synuclein aggregation in vitro.
Welander H; Bontha SV; Näsström T; Karlsson M; Nikolajeff F; Danzer K; Kostka M; Kalimo H; Lannfelt L; Ingelsson M; Bergström J
Biochem Biophys Res Commun; 2011 Aug; 412(1):32-8. PubMed ID: 21798243
[TBL] [Abstract][Full Text] [Related]
13. Research Progress of α-Synuclein Aggregation Inhibitors for Potential Parkinson's Disease Treatment.
Kalsoom I; Wang Y; Li B; Wen H
Mini Rev Med Chem; 2023; 23(20):1959-1974. PubMed ID: 37198991
[TBL] [Abstract][Full Text] [Related]
14. Characterization of fibrillation process of alpha-synuclein at the initial stage.
Tashiro M; Kojima M; Kihara H; Kasai K; Kamiyoshihara T; Uéda K; Shimotakahara S
Biochem Biophys Res Commun; 2008 May; 369(3):910-4. PubMed ID: 18329380
[TBL] [Abstract][Full Text] [Related]
15. Post-translational modification of α-synuclein in Parkinson's disease.
Barrett PJ; Timothy Greenamyre J
Brain Res; 2015 Dec; 1628(Pt B):247-253. PubMed ID: 26080075
[TBL] [Abstract][Full Text] [Related]
16. Comparative Analysis of the Conformation, Aggregation, Interaction, and Fibril Morphologies of Human α-, β-, and γ-Synuclein Proteins.
Jain MK; Singh P; Roy S; Bhat R
Biochemistry; 2018 Jul; 57(26):3830-3848. PubMed ID: 29851342
[TBL] [Abstract][Full Text] [Related]
17. The remarkable conformational plasticity of alpha-synuclein: blessing or curse?
Deleersnijder A; Gerard M; Debyser Z; Baekelandt V
Trends Mol Med; 2013 Jun; 19(6):368-77. PubMed ID: 23648364
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
Lee VM; Trojanowski JQ
Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
[TBL] [Abstract][Full Text] [Related]
19. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
[TBL] [Abstract][Full Text] [Related]
20. The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration.
Mahul-Mellier AL; Burtscher J; Maharjan N; Weerens L; Croisier M; Kuttler F; Leleu M; Knott GW; Lashuel HA
Proc Natl Acad Sci U S A; 2020 Mar; 117(9):4971-4982. PubMed ID: 32075919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
